#ACR2022 #ACR22
12S102. Year in Review ππ»
1st to be discussed was the Gloria Trial
Glucocorticoids effective but safety an issue
#ACR2022 #ACR22
12S102. Year in Review ππ»
Next to the most discussed study of the year
Oral surveillance trial
The CV risk is higher in those with ASCVD - NNH 16π³
#ACR2022 #ACR22
12S102. Year in Review ππ»
Next to the Proderm Study
Cost, thromboembolism a concern in the first positive phase 3 RCT in myositis
#ACR2022 #ACR22
12S102. Year in Review ππ»
it was an exciting year for lupus research
from CAR-T to BDCA2, B-cell and Iberdomide
#ACR2022 #ACR22
12S102. Year in Review ππ»
IV Tocilizumab approved for GCA
and shows GC sparing
Share this Scrolly Tale with your friends.
A Scrolly Tale is a new way to read Twitter threads with a more visually immersive experience.
Discover more beautiful Scrolly Tales like this.